tiziana
life
sciences
announces
planned
spin
stemprinter
new
publicly
listed
company
accustem
sciences
new
york
london
globe
newswire
tiziana
life
sciences
plc
nasdaq
tlsa
aim
tils
tiziana
company
clinical
stage
biotechnology
company
developing
targeted
drugs
cancer
inflammatory
diseases
focused
innovative
therapeutics
oncology
inflammation
infectious
disease
today
announced
plans
demerging
stemprinter
asset
separate
independently
listed
public
company
accustem
sciences
limited
stemprinter
genomic
assay
prognosis
early
late
recurrence
breast
cancer
early
stage
breast
cancer
patients
comparison
study
stemprinter
accurate
oncotype
dx
assay
tiziana
presented
two
posters
american
society
clinical
oncology
asco
showed
stemprinter
outperformed
oncotype
dx
risk
prediction
postmenopausal
breast
cancer
patients
results
demonstrated
stemprinter
risk
score
spare
model
approximately
superior
traditional
clinicopathological
parameters
providing
prognostic
information
tissue
samples
patients
breast
cancer
accurate
lymph
lymph
patients
notably
exact
sciences
purchased
oncotype
dx
assay
genomic
health
billion
company
hold
shareholders
meeting
october
vote
planned
demerger
part
demerger
tiziana
provide
new
entity
cash
accustem
sciences
intends
list
london
stock
exchange
lse
late
potentially
dual
listing
nasdaq
effect
demerger
tiziana
plans
distribute
share
dividend
shareholders
record
date
london
time
october
accustem
sciences
begin
process
seeking
ce
mark
approval
november
anticipated
commercialization
europe
second
quarter
subsequently
company
also
intends
seek
fda
approval
gabriele
cerrone
chairman
tiziana
commented
extremely
pleased
announce
planned
spin
stemprinter
technology
believe
received
proper
valuation
technology
part
tiziana
thus
fulfilling
promise
shareholders
demerge
asset
create
new
public
company
focus
exclusively
commercialization
stemprinter
research
indicates
far
accurate
assay
competitors
gives
us
great
confidence
begin
final
steps
monetizing
important
technology
details
planned
demerger
spin
please
see
company
form
filed
securities
exchange
commission
september
company
website
http
tiziana
life
sciences
tiziana
life
sciences
plc
dual
listed
nasdaq
tlsa
uk
aim
tils
biotechnology
company
focuses
discovery
development
novel
molecules
treat
human
diseases
oncology
inflammation
infectious
diseases
addition
milciclib
company
shortly
initiating
phase
studies
orally
administered
foralumab
crohn
disease
nasally
administered
foralumab
progressive
multiple
sclerosis
foralumab
fully
human
monoclonal
antibody
mab
clinical
development
world
phase
compound
potential
application
wide
range
autoimmune
inflammatory
diseases
crohn
disease
multiple
sclerosis
diabetes
inflammatory
bowel
disease
ibd
psoriasis
rheumatoid
arthritis
modulation
response
desirable
company
accelerating
development
receptor
mab
fully
human
monoclonal
antibody
treatment
inflammation
especially
treatment
hospitalized
patients
severe
respiratory
symptoms
forward
looking
statements
certain
statements
made
announcement
statements
statements
historical
facts
rather
based
company
current
expectations
estimates
projections
industry
beliefs
assumptions
words
anticipates
expects
intends
plans
believes
seeks
estimates
similar
expressions
intended
identify
statements
statements
guarantees
future
performance
subject
known
unknown
risks
uncertainties
factors
beyond
company
control
difficult
predict
could
cause
actual
results
differ
materially
expressed
forecasted
statements
company
cautions
security
holders
prospective
security
holders
place
undue
reliance
statements
reflect
view
company
date
announcement
statements
made
announcement
relate
events
date
statements
made
company
undertake
obligation
release
publicly
revisions
updates
statements
reflect
events
circumstances
unanticipated
events
occurring
date
announcement
except
required
law
appropriate
regulatory
authority
enquiries
united
kingdom
tiziana
life
sciences
plc
gabriele
cerrone
chairman
founder
cairn
financial
advisers
llp
nominated
adviser
liam
murray
jo
turner
optiva
securities
limited
broker
robert
emmet
united
states
investors
dave
gentry
ceo
redchip
companies
dave
